Aziyo Biologics Inc. (AZYO) News
Filter AZYO News Items
AZYO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AZYO News Highlights
- For AZYO, its 30 day story count is now at 5.
- Over the past 21 days, the trend for AZYO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about AZYO are LI, RM and MD.
Latest AZYO News From Around the Web
Below are the latest news stories about AZIYO BIOLOGICS INC that investors may wish to consider to help them evaluate AZYO as an investment opportunity.
Aziyo sheds 56% as FDA cites issues in marketing submission for antibacterial product
|
ACER's Stock Down on Failure of Phase II Study, Cash UpdatesACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down. |
Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial EnvelopeSILVER SPRING, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, provides an update on its submission to the U.S. Food and Drug Administration (FDA) for the CanGaroo® RM Antibacterial Envelope, the Company’s next-generation biomaterial envelope. The device is intended to securely hold a cardiac implantable electronic device or n |
Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company’s management team will host a conference call and webcast with accompanying slides startin |
Aziyo Biologics to Present at the Cowen 43rd Annual Health Care ConferenceSILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on M |
SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsSWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on its team, portfolio, as well as the progress and achievements of its borrower partners. |
Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should KnowAziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year. |
Investors in Aziyo Biologics (NASDAQ:AZYO) have unfortunately lost 38% over the last yearInvestors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can... |
Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline ResultsSILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary (unaudited) net sales results for its fourth quarter and full year ended December 31, 2022. Preliminary Fourth Quarter and Full Year 2022 Net Sales Results Anticipate fourth quarter 2022 net sales of approximately $12.5-$1 |